Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer
Hanane Laklai(Inserm), Corinne Bousquet(Centre National de la Recherche Scientifique), Sophie Le Guellec(Hôpital Rangueil), Séverine Laval(Université Toulouse III - Paul Sabatier), Christiane Susini(Inserm), Martin Hagedorn(Université de Bordeaux), Stéphane Pyronnet(Centre National de la Recherche Scientifique), Marie‐Bernadette Delisle(Inserm), Andrew V. Schally(Tulane University), Laurent Dumartin(Queen Mary University of London), Andréas Bikfalvi(Inserm), Philippe Rochaix(Inserm)
Cited by 36
Related Papers
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study
|The Lancet Neurology|2022|651
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
|Proceedings of the National Academy of Sciences|1999|290
Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma
|The Journal of Pathology|2018|284